alexa Efficacy of Infliximab in Patients with Refractory Uvei
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Efficacy of Infliximab in Patients with Refractory Uveitis Associated with Behcet Disease

Nilüfer Yalçındağ F1, Özge Yanık1* and Nurşen Düzgün2
1Ankara University, Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey
2Ankara University, Faculty of Medicine, Department of Internal Medicine-Rheumatology, Ankara, Turkey
Corresponding Author : Özge Yanık, MD
Ankara University Faculty of Medicine
Department of Ophthalmology
Mamak Cad. Dikimevi, Ankara 06100 Turkey
Tel: +90 506 736 15 99
Fax: +90 312 363 80 82
E-mail: [email protected]
Received: October 08, 2013; Accepted: January 07, 2014; Published: January 17, 2014
Citation: Yalçındağ FN, Yanık Ö, Düzgün N (2014) Efficacy of Infliximab in Patients with Refractory Uveitis Associated with Behçet Disease. J Clin Exp Ophthalmol 5:319. doi:10.4172/2155-9570.1000319
Copyright: © 2014 Yalçındağ FN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


Background: Ocular involvement in Behçet disease is responsible for severe morbidity by causing nongranulomatous panuveitis and retinal vasculitis. In some cases, recurrent attacks cannot be controlled by conventional immunosuppressives and corticosteroid or interferon. The aim of this study is to investigate the efficacy of infliximab treatment in patients with refractory uveitis associated with Behçet disease.

Methods: Nine patients with Behçet disease related uveitis were included in the study. Uveitis had been refractory to treatment with either a combination of cyclosporine-A, azathioprine, and corticosteroid or interferon α-2a monotherapy in all patients. Patients received infliximab infusions (5 mg/kg) at weeks 0, 2, 6, and every 8 weeks thereafter. In patients receiving interferon α-2a at the time of initiation of infliximab therapy, interferon was ceased before starting infliximab. We evaluated visual acuity, ocular inflammatory attacks, and adverse effects.

Results: The Patients consist of seven men and two women; their ages ranging from 28 to 49 years. The mean follow-up after initiating infliximab therapy was 14.4 months. Four of the patients had no ocular inflammatory attacks during follow-up. Two of the remaining five patients developed a mild anterior uveitis only once after the start of infliximab infusions. Three of the patients had a mild panuveitis attack 2-4 months after the initiation of infliximab therapy. Best corrected visual acuity (BCVA) improved at least 2 lines in 6 (33.3%) eyes, from no light perception to hand motion in one eye, and from light perception to hand motion in another eye. BCVA remained stable in 9 (50%) eyes. In one patient, infliximab treatment was terminated owing to HPV+genital warts at 8th month of therapy. No other adverse effects were noticed apart from temporary infusion reaction and urticaria-like rash.

Conclusions: With a follow-up period ranging from seven to thirty three (7-33) months, infliximab was effective and well tolerated in refractory Behçet uveitis.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version